The evidence of ANXA2 overexpression in metastatic lesions, after cells would have undergone MET (and thus re-express E-cadherin), is another indication that EMT is a metastable program with several intermediate steps7 and we reported by the first time in CRC in the present study. The gene discussed is ANXA2; the disease is colorectal carcinoma.